Fortress Biotech Inc  

(Public, NASDAQ:FBIO)   Watch this stock  
Find more results for cndo
+0.02 (0.70%)
Real-time:   2:23PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.82 - 2.93
52 week 1.45 - 5.35
Open 2.84
Vol / Avg. 68,751.00/302,008.00
Mkt cap 130.68M
P/E     -
Div/yield     -
EPS -0.67
Shares 46.82M
Beta 0.85
Inst. own 12%
Aug 10, 2015
Q2 2015 Fortress Biotech Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 11, 2015
Q1 2015 Fortress Biotech Inc Earnings Release
Mar 16, 2015
Q4 2014 Coronado Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2507.00% -
Operating margin -2414.20% -
EBITD margin - -
Return on average assets -55.93% -21.47%
Return on average equity -74.01% -26.86%
Employees 16 -
CDP Score - -


3 Columbus Circle, 15Th Floor
NEW YORK, NY 10019
United States - Map
+1-781-6524500 (Phone)
+1-781-6524545 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer, which include CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. The Company is engaged in planning, identifying, evaluating and acquire, in-license and invest in pharmaceutical and biotechnology products, technologies and companies. CNDO-201 is a biologic that consists of microscopic eggs of the porcine whipworm used in treatment of autoimmune diseases, such as Crohn’s disease (CD), ulcerative colitis (UC), multiple sclerosis (MS), autism, psoriasis and Type 1 diabetes. CNDO-109 is a biologic that activates the immune system’s natural killer, cells to seek and destroy cancer cells that cause hematologic malignancies, including myeloid leukemia and multiple myeloma, as well as breast, prostate and ovarian cancers.

Officers and directors

Lindsay A. Rosenwald M.D. Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Vice Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Lucy Lu M.D. Chief Financial Officer, Executive Vice President
Age: 39
Bio & Compensation  - Reuters
Michael S. Weiss Executive Vice Chairman - Strategic Development
Age: 49
Bio & Compensation  - Reuters
George C. Avgerinos Ph.D. Senior Vice President - Biologics Operations
Age: 61
Bio & Compensation  - Reuters
Kevin J. Horgan M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Malcolm Hoenlein Ph.D. Director
Age: 71
Bio & Compensation  - Reuters
David J. Barrett CPA, Independent Director
Age: 39
Bio & Compensation  - Reuters
Jimmie Harvey Jr., M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
J. Jay Lobell J.D. Independent Director
Age: 51
Bio & Compensation  - Reuters